Please assess the completion status of the following clinical trial:

Trial Title: Study To Confirm Efficacy and Safety of Terlipressin in Hepatorenal Syndrome (HRS) Type 1

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent by participant or legally authorized representative~* Cirrhosis and ascites~* Rapidly progressive worsening in renal function to a serum creatinine (SCr) at least 2.25 mg/dL and meeting a trajectory for SCr to double over 2 weeks~* No sustained improvement in renal function (less than 20% decrease in SCr and SCr at least 2.25 mg/dL) at least 48 hours after diuretic withdrawal and the beginning of plasma volume expansion with albumin~* Discontinues midodrine and octreotide before randomization if applicable~Exclusion Criteria:~* Serum creatinine level greater than 7.0 mg/dL~* At least 1 event of large volume paracentesis (LVP) at least 4 L within 2 days of randomization~* Sepsis and/or uncontrolled bacterial infection~* Less than 2 days anti-infective therapy for documented or suspected infection~* Shock~* Being treatment with or exposure to nephrotoxic agents, nonsteroidal anti-inflammatory drugs, or significant radiographic contrast agents (within the last 4 weeks)~* Estimated life expectancy of less than 3 days~* Superimposed acute liver injury due to drugs, dietary supplements, herbal preparations, viral hepatitis, or toxins, with the exception of acute alcoholic hepatitis~* Proteinuria greater than 500 mg/day~* Evidence of obstructive uropathy or parenchymal renal disease on ultrasound or other imaging~* Tubular epithelial casts, heme granular casts, hematuria or microhematuria (greater than 50 red blood cells per high power field in the absence of recent catheterization) on urinalysis~* Pregnancy; all women of child-bearing age and potential must have a negative pregnancy test~* Cardiovascular disease judged by the investigator to be severe~* Current or recent renal replacement therapy (RRT) within the past 4 weeks~* Participation in other clinical research involving investigational medicinal products within 30 days of randomization~* Transjugular intrahepatic portosystemic shunt (TIPS) within 30 days of randomization~* Use of vasopressors for at least 3 consecutive days within the 14-day screening period - patients receiving any vasopressor other than midodrine and octreotide within 24 hours of qualifying SCr are also excluded, ie, a 24-hour washout is required prior to enrollment~* Known allergy or sensitivity to terlipressin or another component of the study treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Terlipressin (Type: EXPERIMENTAL): Participants receive terlipressin intravenously as a bolus injection, followed by a saline flush. Dose, duration, retreatment and/or discontinuation may be modified by the investigator, per protocol.
- Placebo (Type: PLACEBO_COMPARATOR): Participants receive matching placebo intravenously as a bolus injection, followed by a saline flush. Dose, duration, retreatment and/or discontinuation may be modified by the investigator, per protocol.

Based on this trial design, predict the completion outcome and termination type (if applicable).